Fam-Trastuzumab Deruxtecan in HER2/Neu-Expressing Serous Endometrial Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Fam-Trastuzumab Deruxtecan in HER2/Neu-Expressing Serous Endometrial Cancer

Published:2023-08 Issue:7 Volume: Page:
ISSN:2473-4284
Container-title:JCO Precision Oncology
language:en
Short-container-title:JCO Precision Oncology

Author:

Rose Peter G.¹^ORCID,Kelley Johanna A.¹^ORCID,Feldman Myra²,Krivanek Kevin³^ORCID

Affiliation:

1. Section of Gynecologic Oncology, Women's Health Institute, Cleveland Clinic, Cleveland, OH

2. Section of Abdominal Imaging, Imaging Institute, Cleveland Clinic, Cleveland, OH

3. Department of Pharmacy, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH

Abstract

Trastuzumab deruxtecan treatment of 3 patients with HER2/neu-expressing serous endometrial cancer resulted in objective response

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/PO.23.00063

Reference18 articles.

1. Two pathogenetic types of endometrial carcinoma

2. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers

3. Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice

4. Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis

5. Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutation;npj Precision Oncology;2024-09-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3